![]() ![]() 6 Research has recently shown that sodium–glucose cotransporter 2 inhibitors (SGLT2i) reduce both cardiovascular disease mortality and hospitalization for HF in patients with type 2 diabetes (T2D). 4, 5 Diabetes itself remains a risk for HF hospitalization. HF is also a significant complication of diabetes, 2, 3 and cases of HF associated with diabetes have been shown to have a worse life expectancy than uncomplicated cases. 1 HF is a life-threatening condition that progresses with repeated exacerbations and remissions. Geriatr Gerontol Int 2022 22: 298–304.Īs the population ages, the prevalence of both heart failure (HF) and diabetes mellitus is increasing. As the subgroup, ipragliflozin treatment decreased in left ventricular mass index in participants aged ≥70 years. In this randomized controlled study carried out in patients with type 2 diabetes and heart failure with preserved ejection fraction, 24-week ipragliflozin treatment did not improve left ventricular diastolic function compared with conventional treatment. In the subgroup analysis, ipragliflozin treatment decreased in left ventricular mass index in patients aged ≥70 years and also decreased in NT-proBNP levels in patients with baseline NT-proBNP ≥400 pg/mL. There were no significant differences in the amount of change in E/ e', e', echocardiography parameters, plasma NT-proBNP level, New York Heart Association class, hemoglobin A1c and blood pressure between the two groups. ResultsĪfter 24 weeks of follow up, E/ e' decreased in both groups (ipragliflozin: 11.0 vs 10.4 conventional treatment 10.5 vs 10.1 multivariate-adjusted P = 0.95). Secondary end-points were other parameters of echocardiography, plasma NT-proBNP level, New York Heart Association class, hemoglobin A1c and blood pressure. Primary end-points were the change in E/ e' and e'. A total of eligible 68 participants were randomly assigned into two groups (ipragliflozin group n = 36 conventional treatment group n = 32). We carried out an open-label, multicenter, randomized, two-arm interventional trial. We analyzed changes in diastolic function using echocardiography in patients with type 2 diabetes and heart failure with preserved ejection fraction. We carried out a randomized controlled trial using ipragliflozin. ![]()
0 Comments
Leave a Reply. |